- Home
- BCAB vs BNTC Comparison
BCAB vs BNTC Comparison
Compare BCAB & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | BNTC |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 405.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BCAB | BNTC |
|---|---|---|
| Price | $0.43 | $11.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $1.00 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 1.8M | 218.1K |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $9.70 |
| 52 Week High | $1.43 | $17.15 |
Technical Indicators
Market Signals| Indicator | BCAB | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 31.66 | 42.71 |
| Support Level | $0.63 | $10.99 |
| Resistance Level | $0.82 | $14.39 |
| Average True Range (ATR) | 0.11 | 1.10 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 5.90 | 44.51 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.